Sign up
Healthed-White-on-Blue

New pneumococcal 15-valent conjugate vaccine that includes coverage against serotype 3

Description

In this Product Explainer, Public Health Physician and Infectious Diseases Epidemiologist Prof Paul Van Buynder explains the burden of pneumococcal disease in both children and adult population. He explains why PCV 15 has increased serotype coverage and why improved immunogenicity against serotype 3 is important both from a clinical and public health perspective (5 mins).

Icon 2

NEXT LIVE Webcast

:
Days
:
Hours
:
Minutes
Seconds
Expert panel – A/Prof Samantha Hocking & Dr Terri-Lynne South, facilitated by A/Prof Ralph Audehm

Expert panel – A/Prof Samantha Hocking & Dr Terri-Lynne South, facilitated by A/Prof Ralph Audehm

GLP 1s & Sarcopenia: Fact vs Hype

Dr Deb Mills

Dr Deb Mills

The New Dengue Vaccine – What You Need to Know

Dr Robert Hungerford

Dr Robert Hungerford

Hypertriglyceridaemia – Causes, Assessment & Management of CV Risk

A/Prof Michelle Rodrigues

A/Prof Michelle Rodrigues

Management of Photoageing

Join us for the next free webcast for GPs and healthcare professionals

High quality lectures delivered by leading independent experts

13 October 2026
Register Now
Prof Paul Van Buynder

expert

Prof Paul Van Buynder

Public Health Physician and Infectious Diseases Epidemiologist; Professor, School of Medicine, Griffith University, Queensland

Date published: 1 January 1970

Discover

Healthed

CPD platform